Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Inc.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics on December 2 and set a price target of $131.90. The company’s shares...

Market Cap	$13.68B	P/E Ratio	N/A
52W High	$36.91	52W Low	$15.55
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	31.4%	52W Position	9.5%
Overall Score	39	Value Score	40
Quality Score	57	Technical Score	20

EPS Current Est	$-1.21	EPS Next Est	$-0.82
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SMMT	$17.57	-2.33%	1.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SMMT	$17.57	-2.3%	1.59M
3
4
5
6

SMMT

SMMT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Summit Therapeutics Inc. Data in Excel

Get Summit Therapeutics Inc. Data in Excel